Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node Positive HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01082068
What this trial is testing

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 72
Testing effectiveness (Phase 2)Ended earlyNCT01776008
What this trial is testing

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast Carcinoma+5 more
National Cancer Institute (NCI) 16
Very early researchEnded earlyNCT00651976
What this trial is testing

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 213
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220
What this trial is testing

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Who this might be right for
Breast Cancer
Shuangyue Liu 178
Early research (Phase 1)Ended earlyNCT03596658
What this trial is testing

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
ER+ HER2- Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 4
Large-scale testing (Phase 3)Not Yet RecruitingNCT07061717
What this trial is testing

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Who this might be right for
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474
Not applicableUnknownNCT02597868
What this trial is testing

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Not applicableActive Not RecruitingNCT04597580
What this trial is testing

Personalised Disease Monitoring in Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticEstrogen Receptor-positive Breast Cancer
The Christie NHS Foundation Trust 97
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07730125
What this trial is testing

Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

Who this might be right for
HR-positive, HER2-negative Breast CancerTNBC - Triple-Negative Breast CancerProstate Cancer
CoRegen, Inc. 67
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Testing effectiveness (Phase 2)Study completedNCT01160718
What this trial is testing

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Swiss Cancer Institute 46
Testing effectiveness (Phase 2)Looking for participantsNCT06875128
What this trial is testing

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Who this might be right for
Metastatic Breast Cancer in the Liver
Delcath Systems Inc. 90
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Large-scale testing (Phase 3)Ended earlyNCT01905592
What this trial is testing

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Neoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+3 more
Tesaro, Inc. 216
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Testing effectiveness (Phase 2)Looking for participantsNCT07330544
What this trial is testing

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 118
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07340619
What this trial is testing

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Who this might be right for
Metastatic (Stage IV) Melanoma
UNICANCER 51
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Next Page